Vacinas
Estudo randomizado com mais de 30.000 pacientes mostrou que a vacina da AstraZeneca é segura e teve 74% de eficácia contra infecção sintomática por SARS-CoV-2.
1 Out, 2021 | 20:27h
Comentários no Twitter
In a phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants the incidence of serious adverse effects was low and the vaccine efficacy was 74%. Efficacy was documented in a range of demographic subgroups. #Covid19vaccine https://t.co/hK8q2dD6OT pic.twitter.com/58aXusCS4I
— NEJM (@NEJM) September 29, 2021
The pivotal trial of the Astra-Zeneca vaccine in over 32,000 participants, published today @NEJM.
Vaccine efficacy 74% [95% CI 65,80] vs symptomatic infections; maintained across subgroups,
age > 65: 84% [54,84] https://t.co/ou3nb15Khx pic.twitter.com/dlwRnrvyc0— Eric Topol (@EricTopol) September 29, 2021
[Preprint] Mais dados mostram que intervalos maiores entre as doses de vacina aumentam a resposta imunológica da vacina da Pfizer-BioNTech contra a COVID-19.
27 Set, 2021 | 13:29hComentário: Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine – News Medical
Conteúdos relacionados:
[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.
Study Commentary | Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
Gratidão às vacinas de mRNA.
27 Set, 2021 | 13:28hIn Gratitude for mRNA Vaccines – New England Journal of Medicine
Opinião | Mistura inadequada de pensamento clínico e sistêmico: vacinas em jovens.
27 Set, 2021 | 13:22hInappropriate Mixing Clinical and Systemic Thinking: Vaccines in the Young – Medium
Não, pessoas vacinadas não são “tão capazes” de disseminar coronavírus quanto pessoas não vacinadas.
27 Set, 2021 | 12:46h
Comentário no Twitter
“Vaccinated people are just as likely to spread the coronavirus.”
This isn't true. But some people — even some very smart people — mistakenly believe this.
Dr. @Craig_A_Spencer explains here why, in this really good piece from @TheAtlantic.https://t.co/9D1dngt3oG
— Paul Sax (@PaulSaxMD) September 23, 2021
Vacinas contra COVID-19 e variantes do SARS-CoV-2.
27 Set, 2021 | 12:43hCOVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell
Comentário no Twitter
COVID-19 #vaccines: Keeping pace with SARS-CoV-2 #variants. Timely commentary on understanding #immune correlates and laboratory findings in the context vaccine efficacy from @mugecevik @NathanGrubaugh @VirusesImmunity @p_openshaw https://t.co/o4GoChq5RM #COVID19 #SARSCoV2 pic.twitter.com/UuWqWa711K
— Sri Baqri (Narasimhan) (@Sri_Baqri) September 17, 2021
[Preprint] Terceira dose da vacina da Sinopharm com SARS-CoV-2 inativado induz robustas respostas de células B e T.
27 Set, 2021 | 12:13hComentários:
Sinopharm’s COVID booster reverses antibody decline, enhances cell-based responses – study – Reuters
Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.
27 Set, 2021 | 12:11hConteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
“Não é um jogo de soma zero”: compartilhar vacinas é do interesse de todos os países.
27 Set, 2021 | 12:06h‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews
Artigo original: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports
Comentário no Twitter
"when US has reached the threshold for domestic herd immunity, it would be optimal to donate doses to other countries, as this would allow for a sharp reduction in the inflow of infected individuals from abroad"
– Modeling by @SaadOmer3, @amynmalik & co https://t.co/NFfp39tde6— Ahmed Mushfiq Mobarak (@mushfiq_econ) September 16, 2021
[Comunicado de imprensa – ainda não publicado] J&J afirma que dose de reforço depois de 2 meses propiciou 75% de proteção contra COVID-19 moderada a grave globalmente, sendo 94% desses casos nos EUA.
27 Set, 2021 | 11:39hComunicado de imprensa: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Comentários:
Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT
J&J booster 94% effective against severe COVID, company says – CIDRAP
Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN
Comentários no Twitter
(fio – clique para saber mais)
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson's #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
(fio – clique para saber mais)
First press released results out for the double-dose J&J vax trial, ENSEMBLE 2. With 2 months between doses, efficacy against moderate to severe/critical increased – didn't provide overall efficacy data though. Adverse reactions similar to 1st dose …1/n https://t.co/BmBVtLvEaW
— Hilda Bastian, PhD (@hildabast) September 21, 2021